Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: TV46000-CNS-30072
Highest Development Status: Phase III Product Type: Small molecule
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Data from the study showed that patients who received risperidone had a statistically significant delay in time to relapse as compared to placebo, thus meeting the primary endpoint.